Submacular surgery to remove choroidal neovascularization associated with central serous chorioretinopathy

Cooper, Blake; Thomas, Matthew A.

doi:10.1016/s0002-9394(00)00395-0

Cited by 27 publications

(12 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subsequent reports have suggested that classic CNV (mainly type 2) and polypoidal lesions are possible complications of CSCR and may contribute to visual loss in these eyes. [31][32][33][34] There are even possible challenges of correctly diagnosing CNV in CSCR.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy

Smretschnig

Hagen

Glittenberg

et al. 2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate the results of indocyanine green angiography (ICGA)-guided verteporfin photodynamic therapy (PDT) with half-fluence rate combined with intravitreal application of anti-VEGF in treating choroidal neovascularization (CNV) in chronic central serous chorioretinopathy (CSCR). Patients and methods In this retrospective cohort study 17 consecutive patients with secondary CNV due to chronic CSCR had their diagnosis verified with fluorescein angiography (FA) and ICGA at baseline. All eyes received either intravitreal ranibizumab (IVR) or bevacizumab (IVB). On the consecutive day following the initial IVR/IVB treatment, ICGAguided verteporfin (6 mg/m 2 ) PDT with halffluence rate (25 J/cm 2 ) was performed on every patient. IVR or IVB was rescheduled on a pro re nata regimen. Main outcome measures were changes in visual acuity (VA) according to the ETDRS letter score and changes in the central foveal thickness (CFT). Results Best-corrected VA at baseline was 65.6 letters (±6.7; n = 17) according to the ETDRS letter score. At 12 months, mean ETDRS letter score improved to 71.2 letters (P = 0.34). CFT was 309 μm and decreased to 216 μm at month 12 control (P = 0.0004). Nine eyes (52.9%) received additional treatment with IVR/IVB due to recurrence of subretinal fluid, with an overall mean number of IVR/IVB treatment of 1.8 ± 3.6 per patient with no systemic side effects during 12 months' follow-up. Conclusions IVR or IVB combined with ICGA-guided half-fluence PDT with verteporfin is effective in treating CNV in chronic CSCR, with choroidal hyperpermeability in ICGA, resulting in stable vision and significant reduction of CFT.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy

Smretschnig

Hagen

Glittenberg

et al. 2016

Eye

View full text Add to dashboard Cite

show abstract

“…Given that primate photoreceptors normally renew their outer segments within a 2 mo time period (Young and Bok 1969) and that after experimental retinal detachment, primate outer segments reform quickly (Guerin et al 1993), the normal configuration is thought to return close to normal within 1 to 2 mo. This knowledge forms the foundation for use of subretinal surgery techniques, such as those used by retinal surgeons to remove neovascular membranes (Cooper and Thomas 2000). Subretinal surgery in IRDs carries an added risk of physical stress of the injection damaging the fovea, the most vulnerable area of the retina, because the disease can make this already thin region even thinner.…”

Section: Controversies In the Field Will Gene Augmentation Therapy Prmentioning

confidence: 99%

The Status ofRPE65Gene Therapy Trials: Safety and Efficacy

Pierce

Bennett

2015

Cold Spring Harb Perspect Med

131

View full text Add to dashboard Cite

Several groups have reported the results of clinical trials of gene augmentation therapy for Leber congenital amaurosis (LCA) because of mutations in the RPE65 gene. These studies have used subretinal injection of adeno-associated virus (AAV) vectors to deliver the human RPE65 cDNA to the retinal pigment epithelial (RPE) cells of the treated eyes. In all of the studies reported to date, this approach has been shown to be both safe and effective. The successful clinical trials of gene augmentation therapy for retinal degeneration caused by mutations in the RPE65 gene sets the stage for broad application of gene therapy to treat retinal degenerative disorders.

show abstract

“…The occurrence of CNV in CSCR has been reported to be approximately 4% in cases with chronic retinal pigment epitheliopathy [31]. The mean age of onset of CNV as a complication of CSCR has been reported to be 48-57 years [29,32].…”

Section: Central Serous Chorioretinopathymentioning

confidence: 99%